Figures released by Danish Statistics, the government statistical agency, show that 2005 was a record year for the Danish drug industry, with more than 4.9 billion euros ($5.8 billion) of goods exported, an increase of 13% on the previous year. The main products sold abroad were reme-dies against depression, diabetes and skin disorders.
Commenting on the results, Jan Hylleberg from the Danish Association of the Pharmaceutical Industry (Lif) said that Danish drugmakers had concentrated their R&D on dis-eases that were affecting increasing numbers of people and thinking globally.
Good at innovation
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze